Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases in the United States. Its primary product is Firdapse, used to treat Lambert-Eaton myasthenic syndrome (LEMS). The company also offers Fycompa, a non-competitive selective antagonist at the postsynaptic ionotropic AMPA glutamate receptor, indicated for focal onset seizures and tonic-clonic seizures. Additionally, it provides AGAMREE, a corticosteroid for Duchenne muscular dystrophy. Catalyst Pharmaceuticals has license agreements with BioMarin Pharmaceutical Inc. and a collaboration with Endo Ventures Limited for generic Sabril tablets. The company operates solely in the U.S. market.

Catalyst Pharmaceuticals, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CPRX. The company is based in the United States, and its shares trade in U.S. dollars (USD). As a U.S.-domiciled company listed on a major American exchange, investors can buy and sell CPRX shares through most brokerage platforms. The NasdaqCM is part of the Nasdaq stock exchange, which is known for hosting many biotechnology and healthcare companies.

Catalyst Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes to develop drugs and therapies, often targeting specific diseases. Catalyst focuses on rare diseases, which are conditions that affect a small percentage of the population. Its products include treatments for neurological and muscular disorders, such as LEMS, epilepsy, and Duchenne muscular dystrophy. The biotechnology industry is research-intensive and involves regulatory approvals, clinical trials, and commercialization efforts.

Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida, United States. The company focuses exclusively on the U.S. market, as indicated by its description stating it develops and commercializes medicines for patients living with rare diseases in the United States. Its products are approved and marketed within the U.S., and it does not mention international operations. The headquarters in Coral Gables places it in the Miami metropolitan area, a hub for healthcare and biotech companies.

Catalyst Pharmaceuticals' portfolio includes several key products. Firdapse is approved for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder affecting nerve-muscle communication. Fycompa is a novel non-competitive selective antagonist at the postsynaptic ionotropic AMPA glutamate receptor, used for focal onset seizures and tonic-clonic seizures. AGAMREE is a corticosteroid for Duchenne muscular dystrophy, a genetic disorder causing progressive muscle degeneration. The company also has a collaboration with Endo Ventures Limited to develop and commercialize generic Sabril tablets. These products address significant unmet medical needs in rare diseases.